Google Scholar: cites
Association of fecal and serum profiles with gastrointestinal cancer and chronic inflammatory enteropathy in dogs
Lyngby, Janne G. (University of Copenhagen)
Gòdia, Marta (Universitat Autònoma de Barcelona. Departament de Ciència Animal i dels Aliments)
Brogaard, Louise (University of Copenhagen)
Kristensen, Annemarie T. (University of Copenhagen)
Fredholm, Merete (University of Copenhagen)
Skancke, Ellen (Norwegian University of the Life Sciences)
Morris, Joanna (University of Glasgow)
Dupont, Nana (University of Copenhagen)
Salavati Schmitz, Silke (University of Edinburgh)
Argyle, David (University of Edinburgh)
Sánchez Bonastre, Armando (Universitat Autònoma de Barcelona. Departament de Ciència Animal i dels Aliments)
Bjørnvad, Charlotte R. (University of Copenhagen)
Cirera, Susanna (University of Copenhagen)
Nielsen, Lise N. (University of Copenhagen)

Data: 2022
Resum: Reliable biomarkers to differentiate gastrointestinal cancer (GIC) from chronic inflammatory enteropathy (CIE) in dogs are needed. Fecal and serum microRNAs (miRNAs) have been proposed as diagnostic and prognostic markers of GI disease in humans and dogs. Dogs with GIC have fecal and serum miRNA profiles that differ from those of dogs with CIE. Aims: (a) identify miRNAs that differentiate GIC from CIE, (b) use high-throughput reverse transcription quantitative real-time PCR (RT-qPCR) to establish fecal and serum miRNA panels to distinguish GIC from CIE in dogs. Twenty-four dogs with GIC, 10 dogs with CIE, and 10 healthy dogs, all client-owned. An international multicenter observational prospective case-control study. Small RNA sequencing was used to identify fecal and serum miRNAs, and RT-qPCR was used to establish fecal and serum miRNA panels with the potential to distinguish GIC from CIE. The best diagnostic performance for distinguishing GIC from CIE was fecal miR-451 (AUC: 0. 955, sensitivity: 86. 4%, specificity: 100%), miR-223 (AUC: 0. 918, sensitivity: 90. 9%, specificity: 80%), and miR-27a (AUC: 0. 868, sensitivity: 81. 8%, specificity: 90%) and serum miR-20b (AUC: 0. 905, sensitivity: 90. 5%, specificity: 90%), miR-148a-3p (AUC: 0. 924, sensitivity: 85. 7%, specificity: 90%), and miR-652 (AUC: 0. 943, sensitivity: 90. 5%, specificity: 90%). Slightly improved diagnostic performance was achieved when combining fecal miR-451 and miR-223 (AUC: 0. 973, sensitivity: 95. 5%, specificity: 90%). When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs.
Nota: Altres ajuts: Fund for Disease Control in our Companion Animals A5386
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Biomarker ; CIE ; Mirna qPCR ; Neoplasia ; RT-qPCR ; Small RNA sequencing
Publicat a: Journal of Veterinary Internal Medicine, Vol. 36 (september 2022) , p. 1989-2001, ISSN 1939-1676

DOI: 10.1111/jvim.16530
PMID: 36120988


13 p, 1.1 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2022-12-08, darrera modificació el 2024-01-17



   Favorit i Compartir